Last updated: February 13, 2026
What is the drug associated with NDC 00169-3205?
NDC 00169-3205 corresponds to Ninlaro (ixazomib citrate), an oral proteasome inhibitor marketed by Takeda Pharmaceuticals. approved for multiple myeloma treatment, often used in combination with other therapies.
What is the current market landscape for Ninlaro?
Market Size and Growth
- The multiple myeloma market has expanded significantly in recent years, driven by increasing diagnosis rates and improved treatment options.
- Global multiple myeloma therapeutics reached an estimated $14 billion in 2022. Ninlaro accounts for approximately 5-10% of this market, with potential for growth.
Competition
Ninlaro competes primarily with other proteasome inhibitors, notably:
- Velcade (bortezomib) – Biogen and Millennium Pharmaceuticals
- Kyprolis (carfilzomib) – Amgen
- Pomalyst (pomalidomide) – Johnson & Johnson
In terms of sales, Velcade remains the market leader with >$800 million annually globally. Ninlaro’s sales, reported in Takeda's fiscal reports, totaled approximately $300 million in 2022.
Prescription Trends
- Increasing adoption in frontline and relapsed/refractory settings.
- Growing preference for oral agents, boosting Ninlaro's appeal.
What are the factors affecting Ninlaro’s pricing and market penetration?
Regulatory and Reimbursement Policies
- FDA approval in 2016 expanded indications.
- National health systems and private insurers influence the drug’s market access through reimbursement policies.
- US Medicare and Medicaid policies favor oral agents to reduce administration costs.
Patent Status and Market Exclusivity
- Original patent expiration neared by 2026; however, patent extensions or formulations could prolong exclusivity.
- Biosimilar or generic entry expected post-2026 may impact prices.
Pricing Benchmarks
- Wholesale Acquisition Cost (WAC) for Ninlaro: approximately $7,800 per 28-day treatment cycle in the US.
- Average negotiated prices for insured patients are lower due to rebates and discounts.
What are the projections for Ninlaro's price over the next five years?
Short-term (1-2 years)
- Slight decreases due to increased competition and negotiations.
- Projected average price decline of 3-5% annually in developed markets.
Medium to Long-term (3-5 years)
- Post patent expiration, biosimilar entry could reduce unit prices by 30-50%.
- Price erosion will depend on biosimilar uptake, market size, and regulatory barriers.
Market Volume Projections
- Prescriptions are expected to grow at a compounded annual growth rate (CAGR) of 8-10% over the next five years.
- Total revenues from Ninlaro could range from $400 million to $600 million in 2028, aligning with rising adoption and volume growth, countering some price declines.
Key Factors Influencing Future Pricing
- Regulatory developments impacting patent extensions or biosimilar approvals.
- Market penetration in developing countries will depend on pricing strategies and reimbursement schemes.
- Clinical advancement, such as new combination regimens or superior agents, may influence demand and pricing.
Final Summary
Ninlaro (ixazomib citrate) maintains a significant share of the multiple myeloma franchise with steady growth expected over the next five years. Price stability in the short term will be driven by limited competition; however, upcoming biosimilar entries post-2026 pose a potential for substantial price erosion. Market share growth will depend on prescriber acceptance, reimbursement policies, and the evolving therapeutic landscape.
Key Takeaways
- Ninlaro's current US WAC stands at approximately $7,800 per treatment cycle.
- Sales totaled about $300 million globally in 2022, with a focus on the US and EU markets.
- Future price declines are projected at 3-5% annually in the near term, with larger drops possible after patent expiration.
- Market growth relies on increasing adoption in treatment lines, especially as oral therapies become preferred.
FAQs
1. How does Ninlaro compare to other proteasome inhibitors in terms of pricing?
Ninlaro's WAC is comparable to other oral agents but generally lower than infused options like Velcade, which can reach over $10,000 per cycle. Secret negotiations and rebates significantly alter net prices.
2. When will biosimilars likely enter the market?
Biosimilars for Proteasome inhibitors are scheduled post-2026, assuming approval and market uptake, which could halve or reduce prices by up to 50%.
3. Are there any current patent protections for Ninlaro?
The initial patent is projected to expire around 2026, but patent extensions or formulations may extend exclusivity until 2028 or later in some jurisdictions.
4. How does reimbursement influence Ninlaro’s market prices?
Coverage by insurers, especially Medicare and private payers, constrains list prices due to negotiated discounts as part of formulary decisions.
5. What is the outlook for Ninlaro’s market share in the next five years?
Market share is anticipated to stabilize or slightly grow, driven by growing patient populations and physician familiarity, but long-term growth may be limited by biosimilar competition.
References
- Takeda Pharmaceuticals. Fiscal Year Reports 2022.
- IQVIA. National Sales Data 2022.
- FDA Approvals and Label Updates.
- MarketResearch.com. Multiple Myeloma Therapeutics Market Study 2022.
- Medicare and Medicaid Reimbursement Policies.
